Is INHX a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

183 people get INHX articles and Market Currents by email alert.

Get email alerts on INHX »

HEADLINES:

Merger And Acquisition Deals Could Take These Stocks Higher
Hawkinvest • Thu, Jun 28, 2012
Positive Data Released On Idenix Pharmaceuticals IDX184 Hep C Drug
EXPstocktrader • Tue, Jun 19, 2012 • 5 Comments
Idenix Pharmaceuticals: A Hepatitis C Play Revisited
EXPstocktrader • Tue, Jun 12, 2012
Game Changer: Medgenics' FDA Fast Track Application For Hepatitis
Ray Dirks • Tue, Apr 24, 2012 • 2 Comments
Will Medgenics Become The Next Hepatitis-C Take Over Candidate?
Ray Dirks • Mon, Mar 12, 2012 • 2 Comments
Hepatitis C Remains A Hot Play
The Burrill Report • Mon, Feb 27, 2012
February's Merger Arbitrage Option Plays
Value Research • Tue, Feb 7, 2012 • 2 Comments
Biopharma Report Card: 2-Week Checkup
Scott Matusow • Mon, Feb 6, 2012 • 25 Comments
3 M&A Arbitrage Opportunities
The Financial Lexicon • Sun, Feb 5, 2012 • 2 Comments
Illogical Biotech Valuations Create Value And Value Traps
Brian Nichols • Wed, Feb 1, 2012 • 26 Comments
Easing The Pain: Why Investment In Bio-Pharma Is A Worthy Cause
Scott Matusow • Wed, Feb 1, 2012 • 4 Comments
Canaccord Genuity Rates These 8 Healthcare Stocks A Buy
Kapitall • Tue, Jan 31, 2012
Best Performing Stocks Year To Date
Bespoke Investment Group • Mon, Jan 30, 2012 • 2 Comments
Johnson & Johnson: The Turnaround Is Starting And I Am A Buyer
Smith On Stocks • Mon, Jan 30, 2012 • 16 Comments
Biotech Equities Continue To Benefit From Discoveries And Acquisitions In 2012
Zvi Bar • Fri, Jan 27, 2012 • 1 Comment
2011 Review And Outlook For Biotechnology In 2012
Michael Becker • Wed, Jan 25, 2012 • 2 Comments
Top Hepatitis C Virus Biotech Picks By The World's Largest Fund Managers
GuruFundPicks • Wed, Jan 25, 2012 • 1 Comment
4 Low-Priced Biotech Stocks Poised To Rally In 2012
Rougemont • Tue, Jan 24, 2012 • 4 Comments
Merger Arbitrage Mondays: Jan. 23, 2012
Asif Suria • Mon, Jan 23, 2012 • 5 Comments
2 Major Biotech Trends In 2012
Marc Lichtenfeld • Thu, Jan 19, 2012

To learn more about Seeking Alpha Pro, click here.

4 Reasons Inhibitex Is No Longer A Good Buy
Adam Gefvert • Wed, Dec 7, 2011 • 30 Comments
Inhibitex: $22 For Shares? Don't Believe The Hype, Redux
Jon Slotnick • Mon, Dec 5, 2011 • 20 Comments
Inhibitex Continues Higher, Sets Another Trade Catalyst In Play
M. E. Garza • Wed, Nov 30, 2011 • 3 Comments
Inhibitex: The Negatives Of An Acquisition And The Odds Of It Occurring
Brian Nichols • Fri, Nov 25, 2011 • 7 Comments
Inhibitex: This Is One You Might Want To Grow With
John Mylant • Wed, Nov 9, 2011
Inhibitex Soars On Interferon-Free Hopes
EP Vantage • Wed, Nov 9, 2011 • 2 Comments
Inhibitex's Future Looks Promising
David Zanoni • Mon, Nov 7, 2011
Inhibitex: The Next Hot Pharma Stock
Adam Gefvert • Mon, Nov 7, 2011 • 26 Comments
Inhibitex: Recent Price Action Sees Pressure To Cover Mounting
M. E. Garza • Sun, Oct 9, 2011
Inhibitex Ready for a Breakout Year
Jason Napodano • Fri, Mar 11, 2011 • 8 Comments
Inhibitex Takes Hit After Drug for Shingles Treatment Misses Primary Endpoint
Proactive Investor • Wed, Dec 15, 2010 • 1 Comment
Inhibitex Rates Buy on FV-100 Phase 2 Data
Jason Napodano • Wed, Dec 15, 2010 • 10 Comments
Inhibitex Initiated at Neutral with Significant Upside Potential
Zacks Investment Research • Mon, Sep 21, 2009 • 1 Comment

Merger And Acquisition Deals Could Take These Stocks Higher
Hawkinvest • Thu, Jun 28, 2012
Positive Data Released On Idenix Pharmaceuticals IDX184 Hep C Drug
EXPstocktrader • Tue, Jun 19, 2012 • 5 Comments
Idenix Pharmaceuticals: A Hepatitis C Play Revisited
EXPstocktrader • Tue, Jun 12, 2012
Game Changer: Medgenics' FDA Fast Track Application For Hepatitis
Ray Dirks • Tue, Apr 24, 2012 • 2 Comments
Will Medgenics Become The Next Hepatitis-C Take Over Candidate?
Ray Dirks • Mon, Mar 12, 2012 • 2 Comments
Hepatitis C Remains A Hot Play
The Burrill Report • Mon, Feb 27, 2012
February's Merger Arbitrage Option Plays
Value Research • Tue, Feb 7, 2012 • 2 Comments
Biopharma Report Card: 2-Week Checkup
Scott Matusow • Mon, Feb 6, 2012 • 25 Comments
3 M&A Arbitrage Opportunities
The Financial Lexicon • Sun, Feb 5, 2012 • 2 Comments
Illogical Biotech Valuations Create Value And Value Traps
Brian Nichols • Wed, Feb 1, 2012 • 26 Comments
Easing The Pain: Why Investment In Bio-Pharma Is A Worthy Cause
Scott Matusow • Wed, Feb 1, 2012 • 4 Comments
Canaccord Genuity Rates These 8 Healthcare Stocks A Buy
Kapitall • Tue, Jan 31, 2012
Best Performing Stocks Year To Date
Bespoke Investment Group • Mon, Jan 30, 2012 • 2 Comments
Johnson & Johnson: The Turnaround Is Starting And I Am A Buyer
Smith On Stocks • Mon, Jan 30, 2012 • 16 Comments
Biotech Equities Continue To Benefit From Discoveries And Acquisitions In 2012
Zvi Bar • Fri, Jan 27, 2012 • 1 Comment
2011 Review And Outlook For Biotechnology In 2012
Michael Becker • Wed, Jan 25, 2012 • 2 Comments
Top Hepatitis C Virus Biotech Picks By The World's Largest Fund Managers
GuruFundPicks • Wed, Jan 25, 2012 • 1 Comment
4 Low-Priced Biotech Stocks Poised To Rally In 2012
Rougemont • Tue, Jan 24, 2012 • 4 Comments
Merger Arbitrage Mondays: Jan. 23, 2012
Asif Suria • Mon, Jan 23, 2012 • 5 Comments
2 Major Biotech Trends In 2012
Marc Lichtenfeld • Thu, Jan 19, 2012

There are no Transcripts on INHX.

Biotech Stocks: Achillion, Idenix could miss hep-C merger bonanza

at MarketWatch.com (Feb 1, 2012)
Which Biotech Company Is the Next Takeover Target?

at CNBC.com (Jan 9, 2012)
Stocks Eke Out a Gain Ahead of Earnings

at CNBC.com (Jan 9, 2012)
Movers & Shakers: Monday’s biggest gaining and declining stocks

at MarketWatch.com (Jan 9, 2012)
Stocks on the Move Now

at CNBC.com (Jan 9, 2012)
Futures Rise as Euro Zone Leaders Meet

at CNBC.com (Jan 9, 2012)
What's Shaking: Monday's Early Movers

at CNBC.com (Jan 9, 2012)
Indications: U.S. stock futures trade flat; Netflix gains

at MarketWatch.com (Jan 9, 2012)
Stocks to Watch: Stocks to watch Monday: Inhibitex, Motorola, Alcoa

at MarketWatch.com (Jan 9, 2012)
Option Bulls Target Inhibitex Before Buyout

at CNBC.com (Jan 9, 2012)
Bristol-Myers buying Inhibitex for $2.5 billion

at MarketWatch.com (Jan 8, 2012)
Nobody Doesn't Like Sara Lee: Options Pro

at CNBC.com (Jan 6, 2012)
Movers & Shakers: Tuesday’s biggest gaining & declining stocks

at MarketWatch.com (Nov 29, 2011)
Movers & Shakers: Monday’s biggest gaining and declining stocks

at MarketWatch.com (Nov 7, 2011)
Movers & Shakers: Friday’s biggest gaining & declining stocks

at MarketWatch.com (Nov 4, 2011)
Movers & Shakers: Tuesday’s biggest gaining and declining stocks

at MarketWatch.com (Dec 14, 2010)
Movers & Shakers: Wednesday’s biggest gaining and declining stocks

at MarketWatch.com (Nov 24, 2010)

INHX vs. ETF Alternatives

Company Description

Currently, there's no company description for INHX.

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Friday, January 27, 2012, 8:56 AM Idenix Pharmaceuticals (IDIX) -9.6% after Stifel Nicolaus downgrades shares to Sell from Hold at Stifel Nicolaus, which believes the "significant difference" in potency existing between IDIX's hepatitis C drug and those made by Pharmasset (VRUS) and Inhibitex (INHX) has important implications on how remaining "potential consolidators" strategically view the companies. Comment! [Healthcare, On the Move]
Tuesday, January 24, 2012, 10:36 AM Following a common theme of Hepatitis C-related stocks running together, Achillion Pharmaceuticals (ACHN +12.1%) rallies strongly after Israel-based BioLineRX announces a major development deal. Other Hep-C players to watch: INHX, IDIX, VRTX. Comment! [Healthcare, On the Move]
Wednesday, January 11, 2012, 10:49 AM Fitch maintains Bristol-Myers Squibb's (BMY) debt rating at A+ and its outlook at Negative following the drug company's deal to buy Inhibitex (INHX) for $2.5B. While Bristol has enough cash to pay for Inhibitex, the latter won't provide immediate relief to an expected fall in Bristol's revenues because of the expiration of patents. Comment! [Quick Ideas]
Monday, January 9, 2012, 12:59 PM Other Hepatitis C drug-developers' shares rally on the back of Bristol-Myers (BMY -1.1%) plans to buy Inhibitex (INHX +141%): Idenix Pharmaceuticals (IDIX +34%), Achillion Pharmaceuticals (ACHN +16%) and Vertex Pharmaceuticals (VRTX +4%). Comment! [Healthcare, On the Move]
Monday, January 9, 2012, 5:53 AM Bristol-Myers Squibb (BMY) said over the weekend that it has agreed to buy Inhibitex (INHX) for $2.5B as it looks to boost its pipeline ahead of the loss of patent protection for its blood thinner Plavix. The $26/share bid is over double Inhibitex's $9.87 close on Friday despite its main drug, for hepatitis C, only being in mid-stage trials. (PR) 1 Comment [M&A, Top Stories, Healthcare]
Friday, January 6, 2012, 3:33 PM Shares of Inhibitex (INHX +2.3%) tack on a gain, helped along with a note from Noble Financial's Nathan Cali to clients saying he believes the firm's INX-189 drug increases the chances of a "lucrative" partnership deal or merger in the future. Comment! [On the Move, Healthcare]
Wednesday, January 4, 2012, 6:03 PM Inhibitex (INHX -6.4%) had an interesting day. Shares fell as much as 16% in early trading, apparently due to cautious comments from BofA's Rachel McMinn, who thinks there could be considerable downside if a safety check for the company's INX-189 hepatitis drug turns up any issues. However, shares pared the majority of their losses after other analysts came to Inhibitex's defense. Comment! [Healthcare, On the Move]
Friday, December 30, 2011, 8:05 PM Top five Dow gainers of 2011: MCD +31%, IBM +27%, PFE +24%, HD +20%, KFT +20%. Top S&P gainers: COG +103%, EP +92%, ISRG +81%, MA +69%, BIIB +65%. Top Nasdaq gainers: VRUS +469%, EGAN +412%, SIMO +392%, INHX +308%, TSTF +276%. 1 Comment
Friday, December 16, 2011, 9:59 AM Following news that Pharmasset (VRUS -3.4%) will discontinue Phase 2b trials of its hepatitis drug, other hepatitis-related companies are seeing dramatic share movement. Rallying: VRTX +3.9%, ACHN +1.4%. Declining: INHX -27%, IDIX -13.3%. Comment! [On the Move, Healthcare]
Tuesday, November 29, 2011, 9:11 AM Inhibitex (INHX) gains 6.5% in premarket trading after reporting positive data from clinical tests of its INX-189 hepatitis C treatment and saying it plans to expand its testing to evaluate the effect of various doses. The company notes it will use the proceeds from a 1.9M common stock offering to help support its INHX-189 development in 2012. Comment! [On the Move, Healthcare]
Tuesday, November 29, 2011, 9:00 AM Premarket gainers: STX +9%. CEDC +9%. INHX +7%. ONXX +4%. TS +4%. GOLD +4%. RIMM +3%. TCL +3%.
Losers: TIF -8%. RIG -6%. TLAB -3%. Comment! [On the Move]
Monday, November 21, 2011, 11:02 AM The huge runup in shares of Inhibitex (INHX +32%) following the announcement of the Gilead-Pharmasset deal makes sense to Canaccord Genuity. Analysts with the firm say the premium paid by Gilead (GILD -11.3%) validates the nuc prodrug platform and will "provide a backbone" to the hepatitis C treatment landscape for both INHX and GILD. Comment! [On the Move, Healthcare, Quick Ideas]
Monday, November 21, 2011, 9:00 AM Premarket gainers: GEDU +96%. VRUS +86%. INHX +30%. CLDX +8%. CTIC +6%. CLWR +6%. DNDN +6%. CBE +5%.
Losers: GERN -7%. KYG -6%. GILD -6%. RIO -5%. FRO -5%. RDN -4%. LNKD -4%. MT -4%. AIXG -3%. INVN -3%. GMCR -3%. CIM -3%. RIMM -3%. ANR -3%. BCS -3%. JEF -3%. AKS -3%. MPEL -3%. MU -3%. RMBS -3%. BHP -3%. DB -3%. TM -3%. NOK -3%. IHG -3%. BIDU -3%. PCX -3%. VALE -3%. Comment! [On the Move]
Monday, November 21, 2011, 8:00 AM Shares of Hepatitis C treatment providers Inhibitex (INHX) and Vertex Pharmaceuticals (VRTX) show upward momentum following the news of Gilead's (GILD) blockbuster deal to buy Pharmasset (VRUS). Premarket: INHX +31%, VRTX +2%. Comment! [On the Move]
Tuesday, November 15, 2011, 10:31 AM Canaccord Genuity analyst Randall Stanicky lines up three specialty pharmaceutical stocks with strong catalyst-driven upside potential before year-end: (1) Teva Pharmaceuticals (TEVA -0.3%) on generic Lipitor potential; (2) Inhibitex (INHX -0.1%) ahead of top-line results from INX-189; (3) Raptor (RPTP +0.3%) due to key six-month tolerability data set to be released in Dec. Comment! [Healthcare, Quick Ideas]
Tuesday, November 8, 2011, 9:05 AM Premarket gainers: MSSR +28%. DYN +20%. YPF +7%. BCRX +9%. NBG +6%. ING +6%. DRYS +6%. SIG +6%. FRO +6%. LYG +5%. RAX +5%. RENN +5%. GTAT +4%. PLCM +4%. NVO +3%. ASML +3%. ATVI +3%. DNDN +3%. AMRN +3%. HFC +3%. JEF +3%. EK +3%.
Losers: TRGT -55%. AMLN -9%. JRCC -7%. ALLT -7%. FOSL -7%. LGCY -5%. TGI -5%. PXD -4%. ETP -4%. INHX -3%. ALU -3%. URBN -3%. AZN -3%. Comment! [On the Move]

Shane Blackmon
$SGYP bought a shingles drug from $BMY, which was a $INHX drug before $BMY buyout $1M upfront payment, milestones, single digit royalty
8/23/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Kudrna
EXPstocktrader: The Hepatitis C Gold Rush $IDIX $ILMN $INHX $MRK $VRUS $$ #biotech #KSMT http://bit.ly/zInIwE
2/15/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jonathan Spencer
This $ONTY also got upgraded right? We might have some info for you on $ONTY later for now, Enjoy $INHX
1/9/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dr. Kris
Juicy 9% M&A Arbitrage: $BMY bidding $26/share in cash for $INHX. Stock @ $23.82 --> 9% ROI. This is a nice return for a low risk trade.
1/9/12
Reply (8)

• !Report Abuse
View all 8 replies
John Rayhall: Well Their drugs are not approved yet and while they have had super results there is no guarantee that they will be blockbusters. That's
1/9/12
• !Report Abuse
John Rayhall: All I can think of the 189 compund has a lot of promise though. If this trades lower I'll buy some again.
1/9/12
• !Report Abuse
Add a reply...

140 characters

John Rayhall
Been buying KRO past few days stock is on fire. Adding to CRZO sold MHR, APKT, INHX today and bught some BSX and DXPE. Let it ride! Lol
1/9/12
Reply (4)

• !Report Abuse
View all 4 replies
Hillbilly Stock Star: IF employment gets better MDY's could trend higher imo.
1/9/12
• !Report Abuse
John Rayhall: Ya looks like it will slowly improve, but not sure if it was just bc Dec was a good month or if it's a long term trend.
1/9/12
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
Bristol-Myers (BMY) agreed to buy Inhibitex (INHX) for $2.5 billion, but INHX's market cap is still $1.85 billion. http://reut.rs/xkAV9Z
1/9/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Erick McKitterick
SEC should investigate this! INHX had 2 blocks on Friday. A Feb 10-15 call spread 2K times for 1.35 and a 2.3K May 15 - Aug 25 Call diag!
1/9/12
Reply (5)

• !Report Abuse
View all 5 replies
humahuaca: but Erick, the SEC has much more important stuff to look into. I hear some new videos were released on youporn
1/9/12
• !Report Abuse
Erick McKitterick: No I understand overall it's a drop in the bucket but once again shows common investors are left out to dry without inside info.
1/9/12
• !Report Abuse
Add a reply...

140 characters

Jonathan Spencer
$INHX .... What a surprise huh? $BMY stepped in and bought them out because of their HCV. #amazing move over 200%
1/9/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

talbano
lighting strikes twice BMY buys INHX wish i had more shares http://bit.ly/yBYwkH
1/8/12
Reply (20)

• !Report Abuse
View all 20 replies
John Rayhall: Low 24s now. Higher than 160% premium?
1/9/12
• !Report Abuse
John Rayhall: They say the competing bid would be $34 but now it's at 24.06 just been trading down. I'll wait and see what it does at the open.
1/9/12
• !Report Abuse
Add a reply...

140 characters

talbano
INHX & MAKO look decent, worth keeping on radar
1/6/12
Reply (14)

• !Report Abuse
View all 14 replies
talbano: JR - I figured you would be happy after your doubts on Friday:) Lighting did strike twice. Appreciate the hug..lol
1/8/12
• !Report Abuse
John Rayhall: Happy is not the word good start to the year. Haha no prob :)
1/8/12
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

Dr. Kris
Juicy 9% M&A Arbitrage: $BMY bidding $26/share in cash for $INHX. Stock @ $23.82 --> 9% ROI. This is a nice return for a low risk trade.
1/9/12
Reply (8)

• !Report Abuse
View all 8 replies
John Rayhall: Well Their drugs are not approved yet and while they have had super results there is no guarantee that they will be blockbusters. That's
1/9/12
• !Report Abuse
John Rayhall: All I can think of the 189 compund has a lot of promise though. If this trades lower I'll buy some again.
1/9/12
• !Report Abuse
Add a reply...

140 characters

John Rayhall
Been buying KRO past few days stock is on fire. Adding to CRZO sold MHR, APKT, INHX today and bught some BSX and DXPE. Let it ride! Lol
1/9/12
Reply (4)

• !Report Abuse
View all 4 replies
Hillbilly Stock Star: IF employment gets better MDY's could trend higher imo.
1/9/12
• !Report Abuse
John Rayhall: Ya looks like it will slowly improve, but not sure if it was just bc Dec was a good month or if it's a long term trend.
1/9/12
• !Report Abuse
Add a reply...

140 characters

Erick McKitterick
SEC should investigate this! INHX had 2 blocks on Friday. A Feb 10-15 call spread 2K times for 1.35 and a 2.3K May 15 - Aug 25 Call diag!
1/9/12
Reply (5)

• !Report Abuse
View all 5 replies
humahuaca: but Erick, the SEC has much more important stuff to look into. I hear some new videos were released on youporn
1/9/12
• !Report Abuse
Erick McKitterick: No I understand overall it's a drop in the bucket but once again shows common investors are left out to dry without inside info.
1/9/12
• !Report Abuse
Add a reply...

140 characters

talbano
lighting strikes twice BMY buys INHX wish i had more shares http://bit.ly/yBYwkH
1/8/12
Reply (20)

• !Report Abuse
View all 20 replies
John Rayhall: Low 24s now. Higher than 160% premium?
1/9/12
• !Report Abuse
John Rayhall: They say the competing bid would be $34 but now it's at 24.06 just been trading down. I'll wait and see what it does at the open.
1/9/12
• !Report Abuse
Add a reply...

140 characters

talbano
INHX & MAKO look decent, worth keeping on radar
1/6/12
Reply (14)

• !Report Abuse
View all 14 replies
talbano: JR - I figured you would be happy after your doubts on Friday:) Lighting did strike twice. Appreciate the hug..lol
1/8/12
• !Report Abuse
John Rayhall: Happy is not the word good start to the year. Haha no prob :)
1/8/12
• !Report Abuse
Add a reply...

140 characters

Michael Kudrna
$INHX catching a bid again, watch for more volume $$
12/21/11
Reply (36)

• !Report Abuse
View all 36 replies
Michael Kudrna: Im looking to start adding NOG under 24.50, but want to see TBT hold up first
1/6/12
• !Report Abuse
John Rayhall: YA? Interesting.
1/6/12
• !Report Abuse
Add a reply...

140 characters

cbibuld
stock taking a big hit today. someone has written a report on INHX. Anyone seen it?
1/3/12
Reply (1)

• !Report Abuse
View all 1 replies
John Rayhall: No I haven't seen it I sold the rest of my position today anyway.
1/3/12
• !Report Abuse
Add a reply...

140 characters

John Rayhall
Bought a bunch of INHX on the selloff so far so good. Fortune favors the brave right?!? (gulp) lol :)
12/16/11
Reply (4)

• !Report Abuse
View all 4 replies
458402: great buy!
12/16/11
• !Report Abuse
John Rayhall: Thanks! :)
12/16/11
• !Report Abuse
Add a reply...

140 characters

Joshua Hayes
$INHX continues its run from its 11/21 breakout. $PKT continues its run from its 11/8 breakout. $PZZI another breakout today. $LQDT breakout
12/1/11
Reply (1)

• !Report Abuse
View all 1 replies
John Rayhall: Why the huge move in PZZI?
12/1/11
• !Report Abuse
Add a reply...

140 characters

John Rayhall
Sell INHX on the VRUS pop?
11/21/11
Reply (9)

• !Report Abuse
View all 9 replies
emburns: I thought about buying VRUS last week...
11/21/11
• !Report Abuse
John Rayhall: Impossible to know what's going to happen in the M&A space
11/21/11
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
I don't think I want to bet big on Inhibitex (INHX), but Pharmasset (VRUS) is a winner. http://bit.ly/vl8iO5
11/7/11
Reply (2)

• !Report Abuse
View all 2 replies
talbano: someone is going to have to step up and buy VRUS
11/7/11
• !Report Abuse
Michael Bryant: I'm guessing Merck (MRK) or Pfizer (PFE) will.
11/8/11
• !Report Abuse
Add a reply...

140 characters

Jeremy Richards
(CPST), (GMCR), (INHX), (SIRI), Our Speculative new long positions we started today.
11/4/11
Reply (3)

• !Report Abuse
View all 3 replies
hotnutsjesus: Government contracts and such.
11/4/11
• !Report Abuse
mljpm: I hope so. The stock is in such a tight trading range.
11/4/11
• !Report Abuse
Add a reply...

140 characters

INHX Inhibitex, Inc.

INHX

Inhibitex, Inc.